ArticleAntimicrobial agents and chemotherapy1998
Characterization of a murine monoclonal antibody to Cryptococcus neoformans polysaccharide that is a candidate for human therapeutic studies.
Article in Antimicrobial agents and chemotherapy, 1998. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 175 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
175 citing papers in PubMed, 303 citations in OpenAlex.
- Phase I evaluation of the safety and pharmacokinetics of murine-derived anticryptococcal antibody 18B7 in subjects with treated cryptococcal meningitis.Antimicrobial agents and chemotherapy · 2005Trial
- The Cryptococcus neoformans titanide is a pathogenic cell type that arises from typical yeast cells in response to host conditions.PLoS biology · 2026Article
- Calcium triggersbioRxiv : the preprint server for biology · 2026Article
- Article
- Effects of human immunoglobulins onmBio · 2026Article
- Mannoprotein Cig1 contributes to the immunogenicity of a heat-killed F-box protein Fbp1Infection and immunity · 2026Article
- Reduced growth and biofilm formation at high temperatures contribute to Cryptococcus deneoformans dermatotropism.Disease models & mechanisms · 2025Article
- Article
- Evolutionary uniqueeLife · 2025Article
- Immunometabolic reprogramming in macrophages infected with active and dormantInfection and immunity · 2025Article
- The buoyancy of cryptococcal cells and its implications for transport and persistence ofmSphere · 2024Article
- Will the Real Immunogens Please Stand Up: Exploiting the Immunogenic Potential of Cryptococcal Cell Antigens in Fungal Vaccine Development.Journal of fungi (Basel, Switzerland) · 2024Review
- Article
- Article
- The buoyancy of cryptococcal cells and its implications for transport and persistence ofbioRxiv : the preprint server for biology · 2024Article
- Host-Pathogen Interactions and Correlated Factors That Are Affected in Replicative-AgedJournal of fungi (Basel, Switzerland) · 2024Article
- Cryptococcosis and Cryptococcal Meningitis: A Narrative Review and the Up-to-Date Management Approach.Cureus · 2024Review
- Synthetic Glycans Reveal Determinants of Antibody Functional Efficacy against a Fungal Pathogen.ACS infectious diseases · 2024Article
- Assessing Phagocytosis of Cryptococcus neoformans Cells in Human Monocytes or the J774 Murine Macrophage Cell Line.Methods in molecular biology (Clifton, N.J.) · 2024Article
- Preparation of Biologically Active Fractions Enriched with Glucuronoxylomannan, the Main Antigen of the Cryptococcal Capsule.Methods in molecular biology (Clifton, N.J.) · 2024Article
115 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 5 institutions in 2 countries.
Funding
Abstract
The murine monoclonal antibody (MAb) 18B7 [immunoglobulin G1(kappa)] is in preclinical development for treatment of Cryptococcus neoformans infections. In anticipation of its use in humans, we defined the serological and biological properties of MAb 18B7 in detail. Structural comparison to the related protective MAb 2H1 revealed conservation of the antigen binding site despite several amino acid differences. MAb 18B7 was shown by immunofluorescence and agglutination studies to bind to all four serotypes of C. neoformans, opsonize C. neoformans serotypes A and D, enhance human and mouse effector cell antifungal activity, and activate the complement pathway leading to deposition of complement component 3 (C3) on the cryptococcal capsule. Administration of MAb 18B7 to mice led to rapid clearance of serum cryptococcal antigen and deposition in the liver and spleen. Immunohistochemical studies revealed that MAb 18B7 bound to capsular glucuronoxylomannan in infected mouse tissues. No reactivity of MAb 18B7 with normal human, rat, or mouse tissues was detected. The results show that both the variable and constant regions of MAb 18B7 are biologically functional and support the use of this MAb in human therapeutic trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.